Purple Book product · Reference 351(a)
Besremi
ropeginterferon alfa-2b-njft
Nov 12, 2021
Approved
Reference 351(a)
License type
Rx
Marketing
None
Listed patents
Sourced from the FDA Purple Book · verified Jul 02, 2026
Key dates
Approval
Approval date of this BLA submission.
Nov 12, 2021
4 yr 9 mo ago
Today
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
Nov 12, 2028
in 2 yr 4 mo
Pharmaceutical detail
Strength
500MCG/ML
Dosage form
Injection
Route
Subcutaneous
Presentation
Pre-Filled Syringe
Center
CDER
License number
2155
Product number
001
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Reference product family
View full familyThis is the reference (originator) product. No biosimilars or interchangeables reference it in the Purple Book yet.
Patent list
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
Source provenance
- advanced-searchAdvanced Search · Jul 02, 2026
- monthly-downloadMonthly download · Jul 02, 2026
Change history
- v4Jul 02, 2026
- v3Jul 02, 2026
- v2Jul 02, 2026
Frequently asked questions
Does Besremi have approved biosimilars?
No 351(k) biosimilars or interchangeable biosimilars referencing Besremi are listed in the FDA Purple Book yet.
What is Besremi's BLA number?
Besremi is licensed under BLA 761166, held by PharmaEssentia Corporation.
When was Besremi approved by the FDA?
Besremi was approved by the FDA on Nov 12, 2021.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
